Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.51 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3433731 | 0.87 | AGTR2 (0.43) | PTPN1AGTR2 | |
| SCHEMBL23315195 | 0.84 | PTPN1 (0.55) | PTPN1HDAC8NR1H2NR1H3 | |
| SCHEMBL21881597 | 0.83 | PTPN1 (0.54) | PTPN1HDAC8NR1H2NR1H3 | |
| SCHEMBL12849136 | 0.80 | PTPN1 (0.54) | PTPN1HDAC8NR1H2NR1H3 | |
| SCHEMBL539738 | 0.80 | PTPN1 (0.54) | PTPN1HDAC8NR1H2NR1H3 | |
| SCHEMBL540106 | 0.79 | PTPN1 (0.51) | PTPN1AGTR2HDAC8NR1H2NR1H3 | |
| SCHEMBL6392086 | 0.79 | PTPN1 (0.63) | PTPN1AGTR2HDAC8 | |
| SCHEMBL21881601 | 0.78 | PTPN1 (0.53) | PTPN1HDAC8NR1H2NR1H3UCHL1 | |
| SCHEMBL3697808 | 0.78 | PTPN1 (0.53) | PTPN1HDAC8NR1H2NR1H3UCHL1 | |
| SCHEMBL30471818 | 0.75 | PTPN1 (0.53) | PTPN1AGTR2HDAC8NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9175003-B2 | Substituted azoanthracene derivatives and intermediates for preparation thereof | VTV THERAPEUTICS LLC (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150148539-A1 | Substituted Azoanthracene Derivatives and Intermediates for Preparation Thereof | VTV THERAPEUTICS LLC | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148539-A1 | Substituted Azoanthracene Derivatives and Intermediates for Preparation Thereof | GLP1R, GIPR, GPR119 | PTPN1 534/4885AGTR2 150/4885HDAC8 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.